Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
Caramaschi
Paola
P
Mahamid
Helal
H
Bambara
Lisa Maria
LM
Biasi
Domenico
D
D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000077300:Bosentan; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000378:metabolism; D017291:Clarithromycin / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005385:Fingers / Q000473:pathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D008111:Liver Function Tests; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*; D012883:Skin Ulcer / Q000209:etiology / Q000517:prevention & control; D013449:Sulfonamides / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D000959:Antihypertensive Agents; D013449:Sulfonamides; D017291:Clarithromycin; D000077300:Bosentan